Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
- PMID: 38821484
- DOI: 10.1016/j.clinre.2024.102381
Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
Abstract
In recent years, the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) has been steadily rising, emerging as a major chronic liver disease of global concern. The course of MASLD is varied, spanning from MASLD to metabolic dysfunction associated steatohepatitis (MASH). MASH is an important contributor to cirrhosis, which may subsequently lead to hepatocellular carcinoma. It has been found that PANoptosis, an emerging inflammatory programmed cell death (PCD), is involved in the pathogenesis of MASLD and facilitates the development of NASH, eventually resulting in inflammatory fibrosis and hepatocyte death. This paper reviews the latest research progress on PANoptosis and MASLD to understand the mechanism of MASLD and provide new directions for future treatment and drug development.
Keywords: Apoptosis; Metabolic dysfunction associated steatohepatitis; Metabolic dysfunction-associated steatotic liver disease; Necroptosis; PANoptosis; Pyroptosis.
Copyright © 2024 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review.Metabolism. 2024 Sep;158:155975. doi: 10.1016/j.metabol.2024.155975. Epub 2024 Jul 14. Metabolism. 2024. PMID: 39004396 Review.
-
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3. Diabetologia. 2024. PMID: 38869512 Free PMC article.
-
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.Int J Mol Sci. 2024 Aug 2;25(15):8462. doi: 10.3390/ijms25158462. Int J Mol Sci. 2024. PMID: 39126031 Free PMC article. Review.
-
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.Int J Mol Sci. 2025 Feb 19;26(4):1778. doi: 10.3390/ijms26041778. Int J Mol Sci. 2025. PMID: 40004240 Free PMC article. Review.
-
Hepatocyte programmed cell death: the trigger for inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis.Front Cell Dev Biol. 2024 Jul 12;12:1431921. doi: 10.3389/fcell.2024.1431921. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39071804 Free PMC article. Review.
Cited by
-
Targeting cell death in NAFLD: mechanisms and targeted therapies.Cell Death Discov. 2024 Sep 7;10(1):399. doi: 10.1038/s41420-024-02168-z. Cell Death Discov. 2024. PMID: 39244571 Free PMC article. Review.
-
Killing hepatocellular carcinoma in the NAFLD/NASH stage: a comprehensive perspective on targeting regulated cell death.Cell Death Discov. 2025 Jun 19;11(1):281. doi: 10.1038/s41420-025-02558-x. Cell Death Discov. 2025. PMID: 40537476 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources